Erenumab (Aimovig®)

Assessment Status Assessment process complete
Drug Erenumab
Brand Aimovig®
Indication For the treatment of chronic and episodic migraine in adults who have at least 4 migraine days per month when initiating treatment with erenumab.
Assessment Process
Rapid review commissioned 19/07/2018
Rapid review completed 15/08/2018
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care
Full pharmacoeconomic assessment commissioned by HSE 28/08/2018
Pre-submission consultation with Applicant 24/09/2018
Full submission received from Applicant 22/01/2019
Preliminary review sent to Applicant 01/04/2019
NCPE assessment re-commenced 01/05/2019
Factual accuracy sent to Applicant 31/07/2019
NCPE assessment re-commenced 06/08/2019
NCPE assessment completed 30/09/2019
NCPE assessment outcome Chronic Migraine: The NCPE recommends that erenumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.* Episodic Migraine: The NCPE recommends that erenumab not be considered for reimbursement.*

Technical Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations September 2021